Biotechnology
Technology
Health

Acceleron Pharma

$44.81
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-0.16%) Today
-$0.07 (-0.16%) Today

Why Robinhood?

You can buy or sell XLRN and other stocks, options, ETFs, and crypto commission-free!

About

Acceleron Pharma Inc. Common Stock, also called Acceleron Pharma, is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Read More Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maneates in June 2003 and is headquartered in Cambridge, MA.

Employees
173
Headquarters
Cambridge, Massachusetts
Founded
2003
Market Cap
2.08B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
425.20K
High Today
$45.59
Low Today
$44.81
Open Price
$45.01
Volume
31.28K
52 Week High
$59.59
52 Week Low
$32.53

Collections

Biotechnology
Technology
Health
Biopharmaceutical
Therapy
Pharmaceutical
2013 IPO
US

News

MarketBeatMar 17

Stock Price, News, & Analysis for Acceleron Pharma

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the tre...

1
Yahoo FinanceMar 13

Edited Transcript of XLRN earnings conference call or presentation 27-Feb-19 10:00pm GMT

Q4 2018 Acceleron Pharma Inc Earnings Call Cambridge Mar 1, 2019 (Thomson StreetEvents) -- Edited Transcript of Acceleron Pharma Inc earnings conference call or presentation Wednesday, February 27, 2019 at 10:00:00pm GMT TEXT version of Transcript Scroll to continue with content Ad ================================================================================ Corporate Participants ================================================================================ * Habib J. Dable Acceleron Pharma In...

17
Seeking AlphaMar 5

Acceleron's ACE-083 an Orphan Drug for inherited neurological disorder

The FDA designates Acceleron Pharma's (NASDAQ:XLRN) Fast Track-tagged ACE-083 an Orphan Drug for the treatment of Charcot-Marie-Tooth disease, an inherited neurological disorder characterized by the progressive loss of muscle tissue and touch sensation due to peripheral nerve damage.

3

Earnings

-$0.77
-$0.71
-$0.64
-$0.58
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.